SABR for early-stage lung cancer: Early-adoption and future directions
Abstract
Early-stage lung cancer incidence among older adults is expected to increase due to demographic trends and CT-based screening, yet optimal treatment of lung cancer in the elderly remains controversial. There are several accepted strategies for treating lung cancer including surgery, conventional radiation, and stereotactic ablative body radiotherapy (SABR). However, there are currently no randomized controlled trials to help distinguish the comparative effectiveness of these various strategies. This is an unfortunate omission as lung cancer causes the most deaths among all cancers in the United States (as well as the entire world). SABR holds particular promise as it is a completely non-invasive, ambulatory technique for achieving cure without an operation, thus avoiding the risks of surgery and the associated pre-operative and post-operative costs. To provide fair view of the potential effect on SABR on controlling lung cancer in the United States, a systematic review of SABR with a focus on its achieved outcomes, toxicities, and comparison to conventional radiation and surgical options is presented.
Subject Area
Oncology
Recommended Citation
Shirvani, Shervin, "SABR for early-stage lung cancer: Early-adoption and future directions" (2012). Texas Medical Center Dissertations (via ProQuest). AAI1518784.
https://digitalcommons.library.tmc.edu/dissertations/AAI1518784